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ABSTRACT
Low-dose CT screening for lung cancer is effective but
expensive. Therefore, cheaper or more focused screening
strategies may be required. LungSEARCH is a
randomised prospective trial of 1568 high-risk
individuals (ie, current or former moderate to heavy
smokers with mild/moderate COPD) who undergo either
annual sputum cytology/cytometry testing or no
screening. Those with abnormal sputum then receive
annual CT and fluorescent bronchoscopy for the
remainder of 5 years, to identify early stage lung cancer.
It is hoped that these simple initial tests could identify
those requiring expensive CT scans, and the aim is to
demonstrate a stage shift towards early stage cancers.
Trial registration numbers ISRCTN: ISRCTN80745975,
clinicaltrials.gov: NCT00512746.
INTRODUCTION
The majority of patients with lung cancer (80%)
have advanced disease at the time of diagnosis,
making them ineligible for curative treatment,
which contributes to the low overall 5-year survival
(around 7% in the UK). By contrast, the prospects
for patients with early stage disease are much more
favourable, with a 5-year survival of 60%–70%
among those with stage Ia non-small cell lung
cancer.
In the 1970s screening for lung cancer with chest
radiography identified more cancers than in the
control groups, but there was no improvement in
mortality from the randomised trials. In 2006,
several studies of CT scanning were used to gener-
ate hypotheses after identifying peripheral adeno-
carcinomas in prevalence screens, with the numbers
discovered varying by population and whether the
study group were Asian, where peripheral adeno-
carcinomas are more common.
RECENT OR ONGOING LUNG CANCER
SCREENING TRIALS
The National Lung Cancer Screening Trial (NLST),
in the USA, was the first large randomised study to
show that low-dose CT can identify lung cancers at
an earlier stage in an unselected smoking popula-
tion and, importantly, reduce mortality.1 The trial
assigned 53 452 heavy smokers aged between 55
and 74 years to either three annual CT screens or
chest radiographs. It showed a statistically signifi-
cant 20% reduction in mortality from lung cancer
with CT. However, CT screening is expensive and a
cost-effectiveness analysis based on the NLST
results suggested that the cost per quality adjusted
life year could be as high as US$81 000.2
The results on mortality from the NELSON trial
(conducted in Belgium and The Netherlands) are
due in 2015–2016, and are expected to confirm the
findings of the NLST. Eligible participants were
aged 50–75 years, and moderate to heavy current or
former smokers (who had quit less than 10 years
before). 15 822 participants were enrolled of whom
7915 were assigned to low-dose CT screening at
baseline, then at years 2 and 4; and 7907 individuals
had no screening (only smoking cessation). Interim
results indicate a high cancer detection rate (85%)
and low false-positive rate (1.4%) after three screen-
ing rounds combined and 2-year follow-up; with a
positive predictive value of 40%.3
There are ongoing attempts to use CT more effi-
ciently (including the LungSEARCH trial outlined
below), or biomarkers. The UK Lung Screening
randomised trial uses a validated Liverpool Lung
Project risk model to identify individuals who have
a risk of at least 5% of developing lung cancer in
the next 5 years, and only these are invited to par-
ticipate. They are then randomised to receive either
a single (prevalence) CT scan, or no screening.4
Another ongoing trial (in Scotland) is using a set of
immune antibody markers to identify those at high
risk of lung cancer and then follow these subjects
closely with CT.
LUNG CANCER RISK IN SMOKERS WITH COPD
The first National Health and Nutrition
Examination Survey showed that individuals with
COPD were significantly more likely to develop
lung cancer than those with normal lung function.5
The cumulative risk of developing incident lung
cancers in patients with moderate COPD was 4%
after 5 years, and several other studies have shown
a significant association between impaired lung
function and lung cancer risk. It is also known that
patients with COPD (of all grades of severity) are
at increased risk of developing lung cancer if they
have abnormal sputum cytology. These findings
were used to help justify the LungSEARCH trial.
RATIONALE FOR LUNGSEARCH
Targeting high-risk subjects should increase the
yield of cancers, making it more cost-effective.
COPD represents an additional risk for developing
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lung cancer, as are previous head and neck cancers, asbestos
exposure and more advanced age.
When launched, LungSEARCH was the first trial to focus on
high-risk individuals and to use an initial cheaper screen to iden-
tify those who may have predisposition to lung cancer or have
severe dysplasia/carcinoma in situ and allow detailed
investigation.
In the UK, squamous cell tumours were prevalent, and since
most of these arise from central airways, we wished to
re-explore the value of sputum cytology plus cytometry as a
tool to identify malignant cells and also dysplastic cells, which
could be precursors of malignancy. There was evidence to
suggest that the sensitivity of sputum screening may be signifi-
cantly enhanced by the application of computer-assisted image
analysis (automated image cytometry) to quantitatively analyse
the nuclear structure and DNA content of individual cells.
LUNGSEARCH STUDY DESIGN
Eligible participants were predominantly well but had mild to
moderate COPD (using the Global Initiative for Chronic
Obstructive Lung Disease criteria), and were also either current
smokers with ≥20 pack years smoking history and/or 20-year
duration of smoking, or former smokers who had quit within
8 years with ≥20 pack years smoking history and/or 20-year
duration of smoking.
Participants were randomised to the control group (no inter-
vention) or annual screening for 5 years. The screened group
were asked to provide early morning sputum as the initial
screen, which is a cheap and accessible test. All those with
abnormal sputum results (positive cytology or cytometry) would
then be offered surveillance for up to 5 years using an annual
CT scan and annual autofluorescence bronchoscopy (AFB); the
pathway is summarised in figure 1. Those with normal sputum
results would provide another sample yearly, unless they have an
abnormal result. The majority of published studies on AFB have
shown a significant increase in diagnostic sensitivity for dyspla-
sia and carcinoma in situ. There is also evidence to suggest that
the detection of invasive carcinoma is enhanced by fluorescence
bronchoscopy and this technique has been used to assess
patients with abnormal sputum cytology. The clinicians in each
participating centre would decide from any abnormal broncho-
scopic and/or CT appearances whether follow-up should be
more than annual.
The control subjects were not contacted after randomisation
and are only expected to have an exit chest X-ray at the end of
5 years. Any cancers or deaths would be identified through
patient records or the national cancer registry.
The trial is powered to detect a stage shift between the
screened and control groups; specifically to show that the pro-
portion of cancers that are early stage (I and II) is 50% in the
surveillance group and only 10% in the control group; and for
this we require at least 74 lung cancers.
The screened group were also asked to participate in Lung
reSEARCH, where annual blood and sputum would be collected
and stored in a central tissue bank at Leeds University. All those
undergoing AFB would also be asked to consent to provide
control samples of bronchial mucosa as well as two samples
from any suspicious area, in addition to those samples taken for
pathology. We therefore have the opportunity to follow the
natural history of dysplastic lesions for up to 5 years, providing
an important contribution on the natural history of dysplastic
lesions, whose management remains controversial.
PROGRESS
The study recruited 1568 individuals between August 2007 and
March 2011 (785 in the screened group and 783 controls).
Follow-up finishes in March 2016. Ten centres across the UK
were involved, with COPD patients approached from either the
hospital clinics or local general practitioners (GP) practices.
The centres were in London (Royal Brompton, Chelsea and
Westminster, and University College London Hospital), Leeds,
Cambridge, Leicester, Manchester, Sunderland, Coventry and
Belfast. Recruitment from general practices proved much more
difficult than expected, due mainly to reluctance of the majority
of practices to participate in research. Many demanded payment
for access and a separate grant was obtained to provide funds
for this. The level of GP co-operation was lowest in London.
As of April 2015, 65 lung cancers have been found through
screening, patient medical records or the national cancer regis-
try. Initial results showed an incidence of abnormal sputum
Figure 1 Flow diagram showing what happens to individuals in the screened (surveillance) arm of the LungSEARCH trial. AFB, autofluorescence
bronchoscopy.
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(using either cytology or cytometry) of 23% of those in the
screened arm in the first year, and 15% in the second year
(excluding those who had a previous abnormal sputum).
The study will inform on the value of a simple initial screen
in a high-risk population, the value of annual CT surveillance in
those with sputum dysplasia, the role of annual AFB, the effect
of smoking cessation in this high-risk group and cost-
effectiveness of this screening policy.
If sputum testing in high-risk individuals identifies a group
especially at risk of lung cancer, whose tumour is discovered
during surveillance, and the study demonstrates a stage shift
between the control and the active group, then a larger study
looking at mortality could be performed to confirm the hypoth-
esis generated in this study.
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